Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas Sees Xtandi Patent Cliff a “Critical Phase,” Steps Up Board Oversight via EPM
Astellas Pharma is tightening governance oversight as it heads toward the FY2027 loss of exclusivity for its prostate cancer drug Xtandi (enzalutamide), which an independent outside director described as a “critical phase” for the company. Eriko Sakurai, an independent outside…
To read the full story
Related Article
BUSINESS
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
- US FDA Accepts Shionogi’s Pediatric Fetroja Filing
July 21, 2026
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…